|Table of Contents|

Analysis of DNA mutations in peripheral blood of patients with left and right lung cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2022 03
Page:
451-455
Research Field:
Publishing date:

Info

Title:
Analysis of DNA mutations in peripheral blood of patients with left and right lung cancer
Author(s):
WANG Le1; MENG Lei1; ZHAO Xiaoai1; YANG Jin1; DAI Penggao2; LUO Xiang3
1.Department of Oncology,the First Affiliated Hospital of Medical College，Xi＇an Jiaotong University，Shaanxi Xi＇an 710061,China；2.College of Life Science，Northwestern University，Shaanxi Xi＇an 710069,China;3.Department of Respiratory and Critical Care Medicine,Tongchuan People's Hospital,Shaanxi Tongchuan 727031,China.
Keywords:
left-side and right-side lung cancer; circulating tumor DNA; pathway
PACS:
R734.2
DOI:
10.3969/j.issn.1672-4992.2022.03.015
Abstract:
Objective:To explore the characteristics of tumor mutations in the humoral environment of lung cancer patients and the potential molecular mechanisms that lead to differences in treatment response and prognosis between left-side(LS) and right-side(RS) lung cancer patients.Methods:In this study,high-throughput sequencing of ctDNA of 14 lung cancer patients was performed,and the changes of ctDNA mutation,protein structure and function,and pathways between the LS group and RS group were compared through bioinformatics analysis.Results:We found that the number of mutations and multiple mutations detected in the LS group were significantly more than those in the RS group,and no consistent mutation sites were detected.There was no significant correlation between age,gender,relative mutation abundance and other indicators in the two groups and the primary location of lung cancer,but there were significant differences in the instability of gene-corresponding protein changes and pathways.Conclusion:The results show that there are significant differences in the characteristics of ctDNA mutations of lung cancer patients between the LS group and RS group,which may be one of the reasons for the differences in the treatment response and prognosis of patients with different primary locations.

References:

[1]KOCHER F,HILBE W,SEEBER A,et al.Longitudinal analysis of 2293 NSCLC patients:a comprehensive study from the TYROL registry［J］.Lung Cancer,2015,87(2):193-200.
[2]RIDGE CA,MCERLEAN AM,GINSBERG MS.Epidemiology of lung cancer［J］.Seminars in Interventional Radiology,2013,30(2):93-98.
[3]JIA B,ZHENG Q,QI X,et al.Survival comparison of right and left side non-small cell lung cancer in stage Ⅰ-Ⅲa patients:A Surveillance Epidemiology and End Results(SEER) analysis［J］.Thoracic Cancer,2019,10(3):459-471.
[4]MARTIN J,GINSBERG R J,ABOLHODA A,et al.Morbidity and mortality after neoadjuvant therapy for lung cancer:the risks of right pneumonectomy［J］.The Annals of Thoracic Surgery,2001,72(4):1149-1154.
[5]RODRIGUEZ M,GOMEZ MT,JIMENEZ MF,et al.The risk of death due to cardiorespiratory causes increases with time after right pneumonectomy:a propensity score-matched analysis［J］.European Journal of Cardio-Thoracic Surgery,2013,44(1):93-97.
[6]LI J,ZHANG DC,HE J,et al.The rule of lymph node metastasis of adenosquamous carcinoma of the lung［J］.Chinese Journal of Oncology,2009,31(7):524-527.
[7]YANG Y,SHI C,SUN H,et al.Elderly male smokers with right lung tumors are viable candidates for KRAS mutation screening［J］.Scientific Reports,2016,7(6):e18566.
[8]WAN JCM,MASSIE C,GARCIA-CORBACHO J,et al.Liquid biopsies come of age:towards implementation of circulating tumour DNA［J］.Nature Reviews Cancer,2017,17(4):223-238.
[9]STENSON PD,BALL EV,MORT M,et al.The Human Gene Mutation Database(HGMD) and its exploitation in the fields of personalized genomics and molecular evolution［J］.Current Protocols in Bioinformatics,2012,1(13):1-20.
[10]WILKINS MR,GASTEIGER E,BAIROCH A,et al.Protein identification and analysis tools in the ExPASy server［J］.Methods in Molecular Biology,1999,112(52):571-607.
[11]GEOURJON C,DELEAGE G.SOPMA:significant improvements in protein secondary structure prediction by consensus prediction from multiple alignments［J］.Computer Applications in the Biosciences :CABIOS,1995,11(6):681-684.
[12]YANG CJ,SHAH SA,LIN BK,et al.Right-sided versus left-sided pneumonectomy after induction therapy for non-small cell lung cancer［J］.The Annals of Thoracic Surgery,2019,107(4):1074-1081.
[13]SIMON C,MORENO N,PENALVER R,et al.The side of pneumonectomy influences long-term survival in stageⅠ and Ⅱ non-small cell lung cancer［J］.The Annals of Thoracic Surgery,2007,84(3):952-958.
[14]MATSUDA I,TAKEUCHI K,MIZUGUCHI S,et al.A case of synchronous bilateral lung cancers:EML4-ALK positive adenocarcinoma in the right lung and adenocarcinoma in situ(the former bronchioloalveolar carcinoma) in the left lung［J］.BMC Pulmonary Medicine,2013,13(25):1-4.
[15]SONG Y,HU C,XIE Z,et al.Circulating tumor DNA clearance predicts prognosis across treatment regimen in a large real-world longitudinally monitored advanced non-small cell lung cancer cohort［J］.Translational Lung Cancer Research,2020,9(2):269-279.
[16]NIE W,QIAN J,XU MD,et al.A non-linear association between blood tumor mutation burden and prognosis in NSCLC patients receiving atezolizumab［J］.Oncoimmunology,2020,9(1):e1731072.
[17]NYGAARD AD,HOLDGAARD PC,SPINDLER KL,et al.The correlation between cell-free DNA and tumour burden was estimated by PET/CT in patients with advanced NSCLC［J］.British Journal of Cancer,2014,110(2):363-368.
[18]GUO D,YANG L,YANG J,et al.Plasma cell-free DNA methylation combined with tumor mutation detection in prognostic prediction of patients with non-small cell lung cancer(NSCLC)［J］.Medicine,2020,99(26):e20431.
[19]PLAGNOL V,WOODHOUSE S,HOWARTH K,et al.Analytical validation of a next generation sequencing liquid biopsy assay for high sensitivity broad molecular profiling［J］.PLoS One,2018,13(3):e0193802.
[20]ABBOSH C,BIRKBAK NJ,WILSON GA,et al.Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution［J］.Nature,2017,545(7655):446-451.
[21]LIU L,LIU H,SHAO D,et al.Development and clinical validation of a circulating tumor DNA test for the identification of clinically actionable mutations in nonsmall cell lung cancer［J］.Genes,Chromosomes & Cancer,2018,57(4):211-220.

Memo

Memo:
陕西省自然科学基金（编号:2020JQ-517）；西安交通大学第一附属医院临床研究一般项目（编号:XJTU1AF-CRF-2017-022）;西安交通大学中央高校基本科研业务基金（编号：xzy012021061）
Last Update: 2021-12-31